|
|
|
 Alexander Dömling is Associate Professor at the Departments of Pharmaceutical Sciences and Chemistry at the University of Pittsburgh/USA. He studied Chemistry & Biology at the Technical University Munich and performed his PhD under the guidance of the late Ivar Ugi. Under a prestigious Humboldt fellowship he spent his postdoctoral time in 1995/6 at the Scripps Research Institute in the group of Nobel Laureate Barry Sharpless (La Jolla/California). In 1996 he co-founded the biotech company Morphochem where he had the position vice president chemistry with up to 40 chemists working with him. Later he also founded R&D Biopharmaceuticals, Bacchus Pharma and Fluoriquest Inc. In 2004 he performed his Habilitation in Chemistry at the Technical University Munich. He was guest Professor at the Technical University Vienna and the Leibniz Institute for Plant Biochemistry.
He is author of more than 70 publications, reviews, book contributions and filed more than 20 patents. His research areas comprise different aspects of MCR chemistry, including stereoselective variations, new MCRs, computational MCR and its application in natural product synthesis. Moreover he is interested in applications of MCR reactions to design and discover novel agonists and antagonists of pharmaceutical targets. In recognition of his contributions to combinatorial chemistry he received the 1994 Friedrich-Weygand Price of the Max Bergmann Society. He has published more than 50 original articles and reviews in MCR chemistry. His recent comprehensive review “Recent Developments in Isocyanide Based Multicomponent Reactions in Applied Chemistry” is the most cited Chemical Review in 2006.
In addition to his regular consulting and lecturing on MCR chemistry, he is a short course instructor on MCR chemistry at many Universities and Industries. For companies these courses are typically held in-house. He has also (co)organized several international meetings on MCR chemistry. |